What is Enliven Therapeutics Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Enliven Therapeutics's annualizedGross Profit for the quarter that ended in Dec. 2024 was $0.00 Mil.
Enliven Therapeutics's average Total Assets over the quarter that ended in Dec. 2024 was $315.60 Mil. Therefore, Enliven Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.
Enliven Therapeutics Gross-Profit-to-Asset % Historical Data
The historical data trend for Enliven Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Enliven Therapeutics's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Enliven Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Enliven Therapeutics Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Enliven Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your 